ИГЛЕСИАС Виктор (DE),АЙП Дэвид (US),ТОММС Джеймс (US),ЧЖУ Юнхун (US)
申请号：
RU2013146234/15
公开号：
RU2013146234A
申请日:
2012.03.28
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of selecting duration of triple therapy treatment to achieve a sustained virologic response in a human subject infected with HCV-genotype 1 or genotype of HCV-4, wherein the therapeutic treatment includes triple peginterferon, ribavirin and meritsitabin, said method comprising: obtaining a sample from said human subject and determining the nucleotide present at a single nucleotide polymorphism of rs12979860, wherein the duration of selected ternary therapeutic treatment of 8 weeks and 12 weeks spruce, if said subject carries two alleles C rs12979860, and wherein the duration of selected ternary therapeutic treatment for at least 12 weeks to 48 weeks, if the subject does not carry two C alleles in rs12979860.2. The method of claim 1, wherein for the therapeutic treatment should triple standard therapy (PT) wherein PT and includes peginterferon ribavirin.3. The method of claim 1, wherein meritsitabin given at doses of 1000 mg to 2000 mg per den.4. A method of selecting duration of triple therapy treatment, with or without further conventional therapy (PT) to achieve a sustained virologic response in a human subject infected with HCV genotype-1 or HCV genotype 4, where the triple therapeutic treatment comprises peginterferon, ribavirin and meritsitabin, and wherein said CT includes peginterferon alfa-2a and ribavirin, said method comprising: obtaining a sample from said human subject and determining the presence of nucleotides in a single nucleotide polymorphism of rs12979860, wherein the duration of selected ternary therapeutic treatment of 8 weeks and 12 weeks with or without Later Click1. Способ выбора продолжительности тройного терапевтического лечения для достижения устойчивого вирусологического ответа у человеческого субъекта, инфицированного HCV генотипа-1 или HCV генотипа-4, где тройное терапевтическое лечение включает пэгинтерферон, рибавирин и мерицитабин, причем указанный способ включает:получение образца от указанного человеческого субъекта и оп
